European Journal of Pharmacology · 2024 · 13 citations · 17 references
MedicineCardiologyPharmacologyCardiovascular PharmacotherapyElectrophysiologyMolecular PharmacologyAtrial FibrillationCardiac MedicationsCardiac PhysiologyCardiovascular PathophysiologyCardiovascular PharmacologySodium-glucose Cotransporter 2 InhibitorsAtrial Arrhythmia MechanismsAtrial Electrical RemodelingAtrial Structural RemodelingElectrical StimulationProgrammed Electrical StimulationRemodelingSodium-glucose CotransportSodium-glucose Cotransporter 2 Inhibition
AIM: Atrial fibrillation (AF), the most common arrhythmia, is characterized by atrial electrical and structural remodeling. Previous studies have found that sodium-glucose cotransporter 2 inhibitor (SGLT2i) can protect myocardium in a glucose independent mechanism. But the role of SGLT2i in regulating AF remains largely unknown. This study, we aimed to investigate the effect of Dapagliflozin (DAPA) in reducing AF susceptibility via inhibiting electrical and structural remodeling. METHOD: The mouse model was established by Angiotensin II (2000 ng/kg/min) infusion for 3 weeks, and an in vitro model was generated by stimulating HL-1 and primary mouse fibroblast with Ang II (1 μM) for 24 h. Programmed electrical stimulation, ECG and whole-cell patch clamp were used to detect DAPA effect on atrial electrical remodeling induced by Ang II. To observe DAPA effect on atrial structural remodeling induced by Ang II, we used echocardiographic, H&E and Masson staining to evaluate atrial dilation. To further explore the protective mechanism of DAPA, we adopt in silico molecular docking approaches to investigate the binding affinity of Ang II and CaMKII at Met-281 site. Western blot was to detect expression level of CaMKII, ox-CaMKII, Nav1.5, Kv4.3, Kv4.2, Kchip2, Kir2.1 and Cx40. RESULTS: triggered by Ang II infusion. DAPA could reduce the binding affinity of Ang II and CaMKII at Met-281 site, which indicated that DAPA may directly alleviate the activation of CaMKII caused by Ang II. DAPA could reduce the upregulation of ox-CaMKII caused by Ang II infusion in atrial tissues. Moreover, DAPA also ameliorated the aberrant expression levels of electrical activity related proteins (Nav1.5, Kv4.3, Kv4.2, Kchip2, Kir2.1 and Cx40) and fibrosis related signal pathways (TGF-β1, p-smad/smad) caused by Ang II. Furthermore, we confirmed that DAPA, as well as other SGLT2i (EMPA, CANA), could reverse these abnormalities caused by Ang II incubation in HL-1 cells and primary mouse fibroblasts, respectively. CONCLUSION: Overall, our study identifies DAPA, a widely used SGLT2i, contributes to inhibiting Ang II-induced ox-CaMKII upregulation and electrical and structural remodeling to reduce AF susceptibility, suggesting that DAPA may be a potential therapy of treating AF.
17
A Dynamic Pathway for Calcium-Independent Activation of CaMKII by Methionine Oxidation
Jeffrey R. Erickson, Mei-ling A. Joiner, Xiaoqun Guan et al. · Cell · 2008 · 1.1K citations · Full text
Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus
Thomas A. Zelniker, Marc P. Bonaca, Remo H.M. Furtado et al. · Circulation · 2020 · 452 citations · Full text
Medicine, Cardiology, Pharmacology +17
Vincenzo Quagliariello, Michelino De Laurentiis, Domenica Rea et al. · Cardiovascular Diabetology · 2021 · 364 citations · Full text
Medicine, Cardiology, Pharmacology +17
Oxidized CaMKII causes cardiac sinus node dysfunction in mice
Paari Dominic Swaminathan, Anil Purohit, Siddarth Soni et al. · Journal of Clinical Investigation · 2011 · 210 citations · Full text